这应该是卵巢癌领域的第一个类器官研究，发表于 September 13, 2018，题目是：Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids

本研究共成功制备了33 organoid cultures derived from 22 HGSC patients ! 病人队列详情如下：

最重要的结论是：Somatic mutations discovered in early passages (passage 1-2) of each organoid were compared to the corresponding tumor sample.
可以说是老生常谈了，此前5年间已经有十几篇CNS级别的文章，涉及到了十几个不同癌症种类的研究都是说明了类器官可以很好的还原原位癌的肿瘤特性，所以可以拿来做药敏测试，辅助医疗，个性化医疗。
类器官研究详情: https://mp.weixin.qq.com/s/1I9cCdo0uWluSsE_rK1ngg

类器官及其原位癌匹配非常好

首先是整体的一个匹配度总结表格如下：

简直不能再好的匹配度了：

• A median of 98.2% of mutations identified in the tumors were also found in the matched organoid line
• Similarly, 98.8% of mutations found in the organoids were also present in the parent tumor
• The overall copy number and allelic imbalance across the genome were also similar between
  organoids and parent tumors
  所以很自然的得出结论：The organoids were therefore a close representation of
  the somatic genetic composition of the parent tumor and did not acquire new somatic mutations
  during the short (7-10 day) ex vivo growth period.
  具体细节是从突变碱基的频率，IHC结果来说明匹配情况，也包括SNV/CNV全景图。
  
  
  

  药物敏感性测试结果解读

  药敏结果有意义的前提是，类器官真的能很好的还原其对应的原位肿瘤的特性！！！
  作者并没有公布原始测试数据，数据分析部分描述的也很含糊，我非常怀疑这个类器官及其原位癌高一致性结果。
  不想看后面的药敏数据了。